Navigation Links
Endo Pharmaceuticals and LecTec Settle Patent Dispute
Date:11/11/2009

on with our acquisition of rights to assets, including intellectual property; government regulation of the pharmaceutical industry; our dependence on a small number of products and on outside manufacturers for the manufacture of our products; our dependence on third parties to supply raw materials and to provide services for certain core aspects of our business; new regulatory action or lawsuits relating to our use of controlled substances in many of our core products; our exposure to product liability claims and product recalls and the possibility that we may not be able to adequately insure ourselves; our ability to protect our proprietary technology; our ability to successfully implement our in-licensing and acquisition strategy; the availability of third-party reimbursement for our products; the outcome of any pending or future litigation or claims by the government; our dependence on sales to a limited number of large pharmacy chains and wholesale drug distributors for a large portion of our total net sales; a determination by a regulatory agency that we are engaging in inappropriate sales or marketing activities, including promoting the "off-label" use of our products; the loss of branded product exclusivity periods and related intellectual property; and exposure to securities that are subject to market risk including auction-rate securities the market for which is currently illiquid; and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual reports on Form 10-K, particularly the discussion under the caption "Item 1A, RISK FACTORS" in our annual report on Form 10-K for the year ended December 31, 2008, which was filed with the Securities and Exchange Commission on March 2, 2009. The forward-looking statements in this press release are qualified by these risk factors. These are fact
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Keryx Biopharmaceuticals Announces Poster Presentation Highlighting Clinical Activity of KRX-0401 (Perifosine) at the 51st Annual Meeting of the American Society of Hematology
2. Access Pharmaceuticals Provides Update on MuGard Commercial Launch in North America
3. MAP Pharmaceuticals to Present at the Lazard Capital Markets 6th Annual Healthcare Conference
4. Transcept Pharmaceuticals to Present at Lazard Capital Markets Healthcare Conference on November 17
5. Vion Pharmaceuticals Reports 2009 Third Quarter and Nine-Month Results
6. Keryx Biopharmaceuticals, Inc. Announces Third Quarter 2009 Financial Results
7. Arena Pharmaceuticals Announces Third Quarter 2009 Financial Results and Recent Developments
8. ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the 2009 Annual Meeting of the American College of Allergy, Asthma & Immunology (ACAAI)
9. Bend Research and Vertex Pharmaceuticals Enter New Scientific Collaboration
10. DUSA Pharmaceuticals to Present at the Merriman Curhan Ford Investor Summit 2009
11. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... , Dec. 18, 2014  RESMED INC. (NYSE: ... quarter of fiscal year 2015 results on Thursday, January 22, ... press release with ResMed,s results will be issued after 1:00 ... webcast to discuss operating results and future outlook. ... US Pacific Time and the live webcast of the call ...
(Date:12/19/2014)... INDIANAPOLIS and LYON, France ... (NYSE: LLY ) and Adocia (Euronext Paris: ... focused on developing an ultra-rapid insulin, known as BioChaperone ... type 2 diabetes. BioChaperone Lispro relies on Adocia,s proprietary ... Lilly and Adocia will develop BioChaperone Lispro ...
(Date:12/17/2014)... Revenue and earnings above the previous ... development In the past 2013/14 fiscal year (ended ... to EUR 4.287 billion (last year: EUR 4.190 billion) despite ... EUR 360 million. "Overall, 2013/14 was a successful fiscal year ... President and CEO of Carl Zeiss AG. "Thanks to our ...
Breaking Medicine Technology:ResMed To Announce Second Quarter 2015 Results 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3ZEISS Asserts its Position in Difficult Environment 2
... to Initiate Phase 2b in Second Quarter of 2008 ... - Conference Call Tomorrow at 8:00 a.m. Eastern Time ... Inc.,(Nasdaq: RDEA ) today announced positive preliminary results ... novel,investigational non-nucleoside reverse transcriptase inhibitor (NNRTI), in,patients with human ...
... to Develop Disease Treatments for Diabetic Kidney Disease and ... Retinopathy, Each Multi-Billion-Dollar Drug Markets, JENKINTOWN, Pa., March ... new class of compounds that inhibit the,production of RAGE, ... that a RAGE inhibitor would be an important,addition to ...
Cached Medicine Technology:Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 2Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 3Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load 4Dynamis Therapeutics, Inc. Discovers RAGE Inhibitor 2
(Date:12/19/2014)... Dotinga HealthDay Reporter ... including ibuprofen, might slightly reduce your risk of developing ... of ibuprofen (Advil, Motrin) and naproxen (Aleve) appear to ... 15 percent, the researchers concluded after reviewing nine prior ... sun exposure. These painkillers "have potential ...
(Date:12/17/2014)... 17, 2014 While countless companies tempt patients ... realize the potential dangers of their purchase. Not only is ... a qualified doctor, but patients who buy hCG online are ... there is actually no real hCG present. Illegal internet hCG ... are no safety standards and may contain unknown fillers that ...
(Date:12/17/2014)... December 17, 2014 HeartMath® Inc., ... on stress, heart rate variability (HRV), heart coherence ... its extensive HRV databases and algorithms to chipset ... will enable HeartMath’s partners to offer its HRV ... research, as well as its normative HRV databases ...
(Date:12/17/2014)... 2014 Now in its second year, ... of the best in senior living and home care ... to communities and agencies that have received outstanding online ... the nearly 100,000 providers currently listed on SeniorAdvisor.com, only ... SeniorAdvisor.com Best of 2015 Awards are located all over ...
(Date:12/17/2014)... News) -- Expectant parents should leave prenatal picture-taking to ... Use of ultrasound imaging and heartbeat monitors to ... the agency warns. "Although there is a ... imaging and heartbeat monitors, prudent use of these devices ... an FDA biomedical engineer, said in an agency news ...
Breaking Medicine News(10 mins):Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 2Health News:Common Painkillers May Help Prevent Certain Skin Cancers, Study Finds 3Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 2Health News:Diet Doc Reveals the Real Dangers for Those who Buy hCG Online 3Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:FDA Warns Against Fetal 'Keepsake' Videos 2
... March 6 Pregis Corporation, a leading,international ... and specialty packaging solutions, will conduct an ... quarter and full year results on,Thursday, March ... a.m. CT). The call can be,accessed through ...
... 6 Champions,Biotechnology, Inc. (OTC Bulletin Board: CSBR), a ... results.,Full details of the Company,s financial results are available ... For the three months ended January 31, 2008 the ... of $0.02 compared to a net loss,of $37,198 and ...
... EBITDA up 33%, TORONTO, March 6 /PRNewswire-FirstCall/ - ... products and services to the global life,sciences markets, today ... reported net revenues of $296 million, net income of ... $0.14.,Adjusted EBITDA rose to $40 million, up from $30 ...
... Essilor International, the world leader in,ophthalmic optical products, today announced its audited financial results,for the year ended December 31, 2007., ... 2007 2006(2) ... 2,908.1 2,690.0 ... 482.6 + 9.3%, As a % of revenue ...
... The following is a,statement in response to Patrick Swayze ... CEO of the Pancreatic Cancer,Action Network, the only national ... support, community outreach and,advocacy for a cure., "We ... with,pancreatic cancer and our thoughts go out to him ...
... Letter asks Senate Budget Leaders to Reject Oxygen ... Reform Much More Difficult,to Achieve, Letter Draws ... March 5 The Council for Quality,Respiratory Care ... home oxygen,therapy providers and manufacturers who provide care ...
Cached Medicine News:Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 2Health News:Champions Biotechnology, Inc. Reports Two Cents per Share Earnings for Three Quarters Ended January 31, 2008 3Health News:MDS Reports First Quarter 2008 Results 2Health News:MDS Reports First Quarter 2008 Results 3Health News:MDS Reports First Quarter 2008 Results 4Health News:MDS Reports First Quarter 2008 Results 5Health News:MDS Reports First Quarter 2008 Results 6Health News:MDS Reports First Quarter 2008 Results 7Health News:MDS Reports First Quarter 2008 Results 8Health News:MDS Reports First Quarter 2008 Results 9Health News:MDS Reports First Quarter 2008 Results 10Health News:MDS Reports First Quarter 2008 Results 11Health News:MDS Reports First Quarter 2008 Results 12Health News:MDS Reports First Quarter 2008 Results 13Health News:MDS Reports First Quarter 2008 Results 14Health News:MDS Reports First Quarter 2008 Results 15Health News:MDS Reports First Quarter 2008 Results 16Health News:MDS Reports First Quarter 2008 Results 17Health News:MDS Reports First Quarter 2008 Results 18Health News:MDS Reports First Quarter 2008 Results 19Health News:MDS Reports First Quarter 2008 Results 20Health News:MDS Reports First Quarter 2008 Results 21Health News:MDS Reports First Quarter 2008 Results 22Health News:MDS Reports First Quarter 2008 Results 23Health News:MDS Reports First Quarter 2008 Results 24Health News:MDS Reports First Quarter 2008 Results 25Health News:MDS Reports First Quarter 2008 Results 26Health News:MDS Reports First Quarter 2008 Results 27Health News:MDS Reports First Quarter 2008 Results 28Health News:MDS Reports First Quarter 2008 Results 29Health News:MDS Reports First Quarter 2008 Results 30Health News:MDS Reports First Quarter 2008 Results 31Health News:MDS Reports First Quarter 2008 Results 32Health News:MDS Reports First Quarter 2008 Results 33Health News:Essilor : 2007 Results 2
... for Cardiology is the first digital solution ... modalities both within and outside cardiology. From ... the archival solutions, Agfas combined expertise in ... and their customers to work the way ...
Full Digital Ultrasound System...
... the latest technologies to help expand your ... These advancements increase system utility and provide ... visualization of even the smallest details. And ... information delivery and expedite a higher quality ...
This catheter is intended for ultrasound examination of coronary intravascular pathology ONLY. Intravascular ultrasound imaging is indicated in patients who are candidates for transluminal coronary i...
Medicine Products: